NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

NCT06008691

RecruitingN/A

Sponsor: Fondazione Italiana Linfomi - ETS

Conditions: Non-Hodgkin Lymphoma, B-cell

Interventions: "novel" MAB (alone or in combination)

Countries: Italy

This is a prospective, observational cohort study to evaluate the clinical impact of novel Monoclonal AntiBodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with diagnosis of B-cell NHL and need of treatment (as per guideline indications), both first-line and relapsed or refractory.
* Patients aimed to be treated in indication with a "novel" MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy.
* Signed written informed consent.

Exclusion Criteria:

* Being involved in a prospective interventional trial outside indication.
* Patients treated outside approved indications:

  * 648-approved indication.
  * 5% AIFA support.
  * Compassionate use.
* Age less than 18 years.
* Inability to provide an informed consent.

Locations (61)

Viagrande, Catania, Italy
Pescia, Pistoia, Italy
Alessandria, Italy
Ancona, Italy
Avellino, Italy
Aviano, Italy
Bari, Italy
Barletta, Italy
Bergamo, Italy
Biella, Italy
Bologna, Italy
Brescia, Italy
Cagliari, Italy
Candiolo, Italy
Carrara, Italy
Castelfranco Veneto, Italy
Catania, Italy
Catania, Italy
Civitanova Marche, Italy
Cremona, Italy
Cuneo, Italy
Florence, Italy
Frosinone, Italy
Lido di Camaiore, Italy
Livorno, Italy
Massa, Italy
Milan, Italy
Milan, Italy
Milan, Italy
Milan, Italy
+ 31 more on CT.gov